Your browser doesn't support javascript.
loading
Blood protein predictors of brain amyloid for enrichment in clinical trials?
Ashton, Nicholas J; Kiddle, Steven J; Graf, John; Ward, Malcolm; Baird, Alison L; Hye, Abdul; Westwood, Sarah; Wong, Karyuan Vivian; Dobson, Richard J; Rabinovici, Gil D; Miller, Bruce L; Rosen, Howard J; Torres, Andrew; Zhang, Zhanpan; Thurfjell, Lennart; Covin, Antonia; Hehir, Cristina Tan; Baker, David; Bazenet, Chantal; Lovestone, Simon.
Afiliação
  • Ashton NJ; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK; National Institute for Health Research Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley, National Health Service Foundation, London, UK.
  • Kiddle SJ; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK; MRC Social, Genetic and Developmental Psychiatry Centre, King's College London, London, UK.
  • Graf J; GE Global Research, Niskayuna, NY, USA.
  • Ward M; Proteomics Facility, Institute of Psychiatry, Psychology & Neuroscience, Kings College London, London, UK.
  • Baird AL; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK; Department of Psychiatry, University of Oxford, Oxford, UK.
  • Hye A; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK; National Institute for Health Research Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley, National Health Service Foundation, London, UK.
  • Westwood S; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK; National Institute for Health Research Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley, National Health Service Foundation, London, UK.
  • Wong KV; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
  • Dobson RJ; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK; National Institute for Health Research Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley, National Health Service Foundation, London, UK.
  • Rabinovici GD; Memory and Aging Center, University of California, San Francisco, CA, USA.
  • Miller BL; Memory and Aging Center, University of California, San Francisco, CA, USA.
  • Rosen HJ; Memory and Aging Center, University of California, San Francisco, CA, USA.
  • Torres A; GE Global Research, Niskayuna, NY, USA.
  • Zhang Z; GE Global Research, Niskayuna, NY, USA.
  • Thurfjell L; GE Healthcare Life Sciences, Uppsala, Sweden.
  • Covin A; Janssen Research & Development, Neurosciences, Titusville, NJ, USA.
  • Hehir CT; GE Global Research, Niskayuna, NY, USA.
  • Baker D; Janssen Research & Development, Neurosciences, Titusville, NJ, USA.
  • Bazenet C; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK; National Institute for Health Research Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley, National Health Service Foundation, London, UK.
  • Lovestone S; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK; Department of Psychiatry, University of Oxford, Oxford, UK.
Alzheimers Dement (Amst) ; 1(1): 48-60, 2015 Mar.
Article em En | MEDLINE | ID: mdl-27239491
ABSTRACT

BACKGROUND:

Measures of neocortical amyloid burden (NAB) identify individuals who are at substantially greater risk of developing Alzheimer's disease (AD). Blood-based biomarkers predicting NAB would have great utility for the enrichment of AD clinical trials, including large-scale prevention trials.

METHODS:

Nontargeted proteomic discovery was applied to 78 subjects from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing with a range of NAB values. Technical and independent replications were performed by immunoassay.

RESULTS:

Seventeen discovery candidates were selected for technical replication. α2-Macroglobulin, fibrinogen γ-chain (FGG), and complement factor H-related protein 1 were confirmed to be associated with NAB. In an independent cohort, FGG plasma levels combined with age predicted NAB had a sensitivity of 59% and specificity of 78%.

CONCLUSION:

A single blood protein, FGG, combined with age, was shown to relate to NAB and therefore could have potential for enrichment of clinical trial populations.
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Alzheimers Dement (Amst) Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Alzheimers Dement (Amst) Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Reino Unido